









Markets
/
Stocks
/
nasdaq-mxct
/

MaxCyte Inc

MXCT

1.520USD

-0.100-6.17%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

162.02MMarket Cap

LossP/E TTM



MaxCyte Inc

1.520

-0.100-6.17%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

96 / 207

Overall Ranking

210 / 4720

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

6.344

Target Price

+291.60%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

Growing

The company is in a growing phase, with the latest annual income totaling USD 38.63M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 74.18.

Overvalued

The company’s latest PE is -3.59, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 78.80M shares, decreasing 19.12% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 5.60M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.71.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.09, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 8.51M, representing a year-over-year decrease of 18.43%, while its net profit experienced a year-over-year decrease of 31.81%.

Score

Industry at a Glance

Previous score

6.09

Change



Financials

7.54

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.31

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.87

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.65

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -3.83, which is 177.02% below the recent high of -10.60 and -260.91% above the recent low of -13.81.

Score

Industry at a Glance

Previous score

2.80

Change

1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 96/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.29, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for MaxCyte Inc is 5.72, with a high of 9.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.29

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

6.344

Target Price

+291.60%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

MaxCyte Inc

MXCT

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 7.83, which is higher than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 1.73 and the support level at 1.42, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.83

Change

-1.53

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.080

Neutral

RSI(14)

50.440

Neutral

STOCH(KDJ)(9,3,3)

71.187

Sell

ATR(14)

0.073

High Vlolatility

CCI(14)

132.590

Buy

Williams %R

35.484

Buy

TRIX(12,20)

-0.303

Sell

StochRSI(14)

41.784

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.514

Buy

MA10

1.475

Buy

MA20

1.431

Buy

MA50

1.692

Sell

MA100

2.003

Sell

MA200

2.861

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 73.92%, representing a quarter-over-quarter decrease of 4.74%. The largest institutional shareholder is The Vanguard, holding a total of 5.60M shares, representing 5.25% of shares outstanding, with 2.30% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Cadian Capital Management LP

10.03M

+7.31%

BlackRock Institutional Trust Company, N.A.

7.41M

+0.87%

Mirabella Financial Services LLP

3.70M

The Vanguard Group, Inc.

Star Investors

5.57M

+2.50%

Vitruvian Partners LLP

5.04M

Morgan Stanley & Co. LLC

3.44M

+1117.21%

Mudita Advisors LLP

3.33M

+3.26%

River Global Investors LLP

3.25M

+57.73%

Morgan Stanley Investment Management Inc. (US)

3.55M

-13.36%

Geode Capital Management, L.L.C.

2.58M

+4.16%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.05, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.21. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.